1.44

6.67% 0.09

After Hours: 1.49 0.05 +3.47%

Reviva Pharmaceuticals Holdings Inc (RVPH)

Overview News Price History Option Chain Financials Discussions Forecast

Reviva Pharmaceuticals Holdings Inc stock is traded at $1.44, with a volume of 297.51K. It is up +6.67% in the last 24 hours and up +28.57% over the past month. Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Previous Close:

$1.35

Open:

$1.37

24h Volume:

297.51K

Relative Volume:

0.63

Market Cap:

$47.65M

Revenue:

Net Income/Loss:

$-37.65M

P/E Ratio:

-1.0213

EPS:

-1.41

Net Cash Flow:

$-24.14M

1W Performance:

+16.13%

1M Performance:

+28.57%

6M Performance:

-61.90%

1Y Performance:

-70.49%

1-Day Range:

$1.33

$1.44

1-Week Range:

$1.20

$1.45

52-Week Range:

$0.60

$6.80

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name

Reviva Pharmaceuticals Holdings Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(408) 501-8881

Address

10080 N WOLFE ROAD, CUPERTINO

Employee

Twitter

Next Earnings Date

2024-08-12

Latest SEC Filings

RVPH's Discussions on Twitter

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-24-22	Initiated	H.C. Wainwright	Buy

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News

Sep 26, 2024

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times

Sep 26, 2024

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - GlobeNewswire

Sep 26, 2024

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - StockTitan

Sep 26, 2024

Sep 23, 2024

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports

Sep 23, 2024

EF Hutton Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation - MSN

Sep 23, 2024

Sep 18, 2024

RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Sep 18, 2024

Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex

Sep 18, 2024

Sep 16, 2024

RVPH: RECOVER Biomarker KOL Event - Yahoo Finance

Sep 16, 2024

Sep 13, 2024

Closing Strong: Reviva Pharmaceuticals Holdings Inc. (RVPH) Ends at 1.12, Down -13.85 from Last Close - The Dwinnex

Sep 13, 2024

Sep 10, 2024

A stock that deserves closer examination: Reviva Pharmaceuticals Holdings Inc. (RVPH) - US Post News

Sep 10, 2024

Sep 09, 2024

Reviva reports positive schizophrenia trial results - Investing.com India

Sep 09, 2024

Reviva reports positive schizophrenia trial results - Investing.com

Sep 09, 2024

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - GlobeNewswire

Sep 09, 2024

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - StockTitan

Sep 09, 2024

Sep 04, 2024

How to interpret Reviva Pharmaceuticals Holdings Inc. (RVPH)’s stock chart patterns - US Post News

Sep 04, 2024